Clinical Trial

PANK-003 Cell Injection Combined with Standard Adjuvant Chemotherapy After Surgery in Patients with Solid Tumors

Name: PANK-003 Cell Injection Combined with Standard Adjuvant Chemotherapy After Surgery in Patients with Solid Tumors — clinical trial record (NCT06897228)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

A single-center, single-arm, dose-escalation exploratory clinical trial on the safety and efficacy of PANK-003 cell injection(Peripheral blood-derived allogeneic natural killer cells )combined with standard adjuvant chemotherapy after surgery in patients with solid tumors

Trial Details

NCT Number	NCT06897228
Lead Sponsor	Shenzhen Celconta Life Science Co., Ltd.
Conditions	Solid Tumors, Adult
Enrollment	18 participants
Start Date	2024-02-18
Primary Completion	2027-01 (estimated)
Study Completion	2027-03 (estimated)
Updated on ClinicalTrials.gov	2025-03-26